GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Dawnrays Pharmaceutical (Holdings) 2348.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

0.91

0.00%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥1.43bn

FY2016FY2025

Net income

CN¥249.2m

FY2016FY2025

Free cash flow

CN¥274.8m

FY2016FY2025

Shareholders' equity

CN¥3.94bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥1.43bnCN¥1.06bnCN¥1.34bnCN¥1.49bnCN¥1.36bnCN¥1.19bnCN¥1.11bnCN¥1.11bnCN¥1.03bnCN¥959.9m
Gross profitCN¥649.1mCN¥577.6mCN¥747.0mCN¥892.8mCN¥786.4mCN¥635.3mCN¥608.7mCN¥692.9mCN¥653.9mCN¥595.6m
Research and developmentCN¥97.2mCN¥70.8mCN¥105.7mCN¥92.6mCN¥78.1mCN¥69.9mCN¥65.3mCN¥54.0mCN¥41.5mCN¥31.1m
Operating incomeCN¥267.4mCN¥367.9mCN¥323.0mCN¥491.9mCN¥443.4mCN¥373.2mCN¥338.1mCN¥401.8mCN¥398.3mCN¥359.9m
Net incomeCN¥249.2mCN¥564.9mCN¥379.6mCN¥417.0mCN¥417.1mCN¥312.2mCN¥297.4mCN¥354.0mCN¥341.2mCN¥309.7m
Diluted earnings per share0.170.370.250.280.280.200.190.220.210.19

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥4.67bnCN¥4.01bnCN¥4.22bnCN¥4.28bnCN¥3.89bnCN¥3.38bnCN¥3.24bnCN¥2.76bnCN¥2.54bnCN¥2.20bn
Cash and short-term investmentsCN¥1.84bnCN¥1.37bnCN¥1.24bnCN¥1.16bnCN¥966.8mCN¥1.09bnCN¥712.0mCN¥1.41bnCN¥1.26bnCN¥1.03bn
Total liabilitiesCN¥724.0mCN¥682.6mCN¥889.0mCN¥1.19bnCN¥1.10bnCN¥838.6mCN¥885.1mCN¥518.0mCN¥436.7mCN¥290.7m
DebtCN¥90.3mCN¥34.7mCN¥120.5mCN¥8.4mCN¥23.5mCN¥2.9mCN¥219.7m——CN¥9.1m
Shareholders' equityCN¥3.94bnCN¥3.32bnCN¥3.32bnCN¥3.08bnCN¥2.77bnCN¥2.53bnCN¥2.36bnCN¥2.24bnCN¥2.10bnCN¥1.91bn
Shares outstanding1,505m1,509m1,502m1,503m1,512m1,540m1,557m1,586m1,587m1,605m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥413.9mCN¥220.2mCN¥394.1mCN¥505.7mCN¥457.8mCN¥352.7mCN¥321.2mCN¥319.4mCN¥455.0mCN¥372.9m
Capital spending−CN¥139.0m−CN¥175.6m−CN¥246.9m−CN¥238.0m−CN¥364.6m−CN¥162.0m−CN¥39.4m−CN¥19.6m−CN¥18.3m−CN¥29.6m
Free cash flowCN¥274.8mCN¥44.6mCN¥147.2mCN¥267.7mCN¥93.2mCN¥190.7mCN¥281.8mCN¥299.8mCN¥436.7mCN¥343.3m
Dividends paid−CN¥154.8m−CN¥111.2m−CN¥136.3m−CN¥115.9m−CN¥167.6m−CN¥95.0m−CN¥119.8m−CN¥236.4m−CN¥106.4m−CN¥118.1m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
RevenueCN¥626.8mCN¥699.2mCN¥734.1mCN¥482.9mCN¥577.4mCN¥501.2mCN¥756.8mCN¥761.8m
Gross profitCN¥322.3mCN¥311.7mCN¥337.4mCN¥219.7mCN¥312.3mCN¥285.5mCN¥414.6mCN¥440.6m
Operating incomeCN¥134.0mCN¥140.9mCN¥126.5mCN¥57.6mCN¥145.4mCN¥240.3mCN¥222.6mCN¥227.0m
Net incomeCN¥141.6mCN¥127.4mCN¥121.8mCN¥71.9mCN¥493.0mCN¥70.1mCN¥298.0mCN¥217.1m
Diluted earnings per share0.090.080.080.050.330.050.200.14
Cash from operations—CN¥196.0mCN¥235.0mCN¥48.0mCN¥171.0mCN¥169.0mCN¥224.0mCN¥192.0m
Capital spending—−CN¥33.0m−CN¥67.0m−CN¥3.0m−CN¥129.0m−CN¥36.0m−CN¥195.0m−CN¥40.0m
Free cash flow—CN¥163.0mCN¥168.0mCN¥45.0mCN¥42.0mCN¥133.0mCN¥29.0mCN¥152.0m
Total assetsCN¥4.64bnCN¥4.67bnCN¥4.52bnCN¥4.01bnCN¥4.04bnCN¥4.22bnCN¥4.14bnCN¥4.28bn
Cash and short-term investmentsCN¥1.85bnCN¥1.84bnCN¥1.89bnCN¥1.37bnCN¥1.69bnCN¥1.24bnCN¥1.20bnCN¥1.26bn
DebtCN¥5.2mCN¥90.3mCN¥10.7mCN¥34.7mCN¥188.1mCN¥140.4mCN¥39.0mCN¥9.8m
Shareholders' equityCN¥4.00bnCN¥3.94bnCN¥3.85bnCN¥3.32bnCN¥3.27bnCN¥3.32bnCN¥3.27bnCN¥3.08bn

Financial ratios

Data as of 1 Nov 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin45.3%54.5%55.7%60.0%58.0%53.3%
Operating margin18.5%19.1%36.1%34.3%32.7%32.8%
Net margin17.4%53.3%28.3%28.0%30.7%26.2%
Return on equity6.3%17.0%11.4%13.6%15.0%12.4%
Return on assets5.3%14.1%9.0%9.7%10.7%9.2%
Free cash flow yield34.3%28.5%39.8%46.2%50.8%31.2%
Revenue growth16.1%-7.9%-9.9%9.7%13.8%7.8%
Earnings growth-62.1%73.3%-9.0%-0.0%33.6%5.0%
Current ratio4.64x3.97x2.57x1.87x2.17x3.23x
Debt to equity0.02x0.01x0.04x0.00x0.01x0.00x
Equity ratio84.4%82.9%78.8%71.9%71.3%74.7%
Interest coverage458.51x56.00x419.66x1182.69x594.01x69.62x
R&D as a share of sales6.8%6.7%7.9%6.2%5.8%5.9%
Buybacks as a share of market value0.3%-0.5%0.1%0.6%1.8%1.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-1.2%3.7%2.3%
Operating income-18.4%-6.4%-4.1%
Net income-15.8%-4.4%-3.4%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin49.2%53.9%54.5%56.8%
Operating margin25.5%27.3%28.8%31.5%
Net margin32.6%30.3%29.7%30.2%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings6.63.13.84.35.05.86.75.88.310.8
Price to sales1.11.61.11.21.51.51.81.92.83.5

Dividends and splits

Per share, in the currency the company pays

Paid for 23 years. Last went ex-dividend on 22 Sept 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.0540.0630.080.0880.080.0650.0580.075
  • 2-for-1 split · 6 Aug 2018

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.